UK markets close in 5 hours 4 minutes
  • FTSE 100

    6,934.19
    -65.89 (-0.94%)
     
  • FTSE 250

    22,373.18
    -117.68 (-0.52%)
     
  • AIM

    1,243.86
    -7.99 (-0.64%)
     
  • GBP/EUR

    1.1592
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.3974
    -0.0010 (-0.07%)
     
  • BTC-GBP

    39,892.18
    -949.32 (-2.32%)
     
  • CMC Crypto 200

    1,259.13
    -39.82 (-3.07%)
     
  • S&P 500

    4,163.26
    -22.21 (-0.53%)
     
  • DOW

    34,077.63
    -123.04 (-0.36%)
     
  • CRUDE OIL

    63.98
    +0.60 (+0.95%)
     
  • GOLD FUTURES

    1,768.60
    -2.00 (-0.11%)
     
  • NIKKEI 225

    29,100.38
    -584.99 (-1.97%)
     
  • HANG SENG

    29,135.73
    +29.58 (+0.10%)
     
  • DAX

    15,241.06
    -127.33 (-0.83%)
     
  • CAC 40

    6,211.39
    -85.30 (-1.35%)
     

InnoCare Appoints Dr. Sean Zhang as Chief Medical Officer

·3-min read

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Dr. Sean Zhang as Chief Medical Officer (CMO). Reporting to the Co-founder, Chairwoman and CEO, Dr. Jasmine Cui. Dr. Zhang will be responsible for global clinical development strategy and execution for InnoCare. Dr. Zhang is based in U.S., thus demonstrating InnoCare’s ongoing commitment to globalization.

As a physician scientist, Dr. Zhang has more than 30 years working experience in clinical practice, academic research and drug discovery and development. Before joining InnoCare, Dr. Zhang served as CMO and Member of the Board of Directors of Hengrui Therapeutics Inc. (HTI) before his promotion to CEO. HTI is a joint venture between Jiangsu Hengrui Medicine and a leading global investment firm focused on oncology, autoimmune and other unmet medical-need disease areas. Under Dr. Zhang’s leadership, his team has successfully launched two global phase III oncology studies in US and EU and one global phase II study for autoimmune disease, submitted more than ten U.S. FDA Investigational New Drug applications (INDs) and conducted a number of successful FDA meetings on several major development programs. Before HTI, Dr. Zhang assumed increasing responsibilities in clinical development at GlaxoSmithKline, Bristol-Myers Squibb, and Johnson and Johnson. He also worked as staff gastroenterologist and clinical investigator at 301 Hospital in Beijing in his early career.

"It is my pleasure to welcome Dr. Zhang to join InnoCare," said Dr. Cui. "We established this senior role in U.S. to not only expand our global footprint but also to enhance our clinical development competency globally. Dr. Zhang has accumulated solid experience in clinical development, drug discovery and business leadership, and he has established a broad network with physicians in both the U.S. and China. I believe his on-boarding will further advance our ongoing clinical trials in the field of oncology and autoimmune diseases worldwide."

"It is my honor and privilege to join InnoCare at this exciting moment in the company’s evolution," said Dr. Zhang. "I am very impressed with InnoCare’s strong innovation capabilities and rich product pipelines. I look forward to working closely with our clinical team and partners to further advance our clinical development pipelines to benefit patients worldwide."

Dr. Zhang completed his postdoctoral training at Sepulveda VA Hospital of UCLA School of Medicine in Los Angeles and Michigan State University. After passing the United States Medical License Examination (USMLE), Dr. Zhang completed his medical followship training at Clinical Center of U.S. National Institute of Health in 2006. He was elected Fellow of American College of Clinical Pharmacology (FCP) in 2012. He is also board of director of Sino-American Pharmaceutical Association (SAPA).

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210228005047/en/

Contacts

Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com

Investor Relations
86-10-66609999
ir@innocarepharma.com